Update on Merck Phase 2/3 INSIGNIA-PAH clinical trial investigating inhaled treatment MK-5475 in pulmonary arterial hypertension

Merck’s investigational inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 was well-tolerated and showed promise among adults with pulmonary arterial hypertension (PAH) in a Phase 1 clinical trial (see our article on this topic at this link). Merck is sponsoring a Phase 2/3 study.

Learn more about the INSIGNIA-PAH trial at this link on the Merck website and on the clinicaltrials.gov website here

MK-5475 belongs to the same family of treatments as riociguat, the first soluble guanylate cyclase (sGC) stimulator to be approved, which is administered orally. Read more on the dedicated PH-KSP page on treatments.

Scroll to Top